Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
China flag China · Delayed Price · Currency is CNY
17.64
-1.16 (-6.17%)
Nov 13, 2026, 3:00 PM CST

SHA:688298 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
976.28930.56811.28812.348,74110,152
Other Revenue
16.8216.8216.647.8127.2316.98
993.1947.38827.92820.168,76810,169
Revenue Growth
17.93%14.43%0.95%-90.65%-13.78%211.43%
Cost of Revenue
599.46586.63659.26640.515,1582,682
Gross Profit
393.64360.75168.66179.643,6107,487
Selling, General & Admin
598.69593.3597.01534.55755.811,133
Research & Development
186.4230.81290.49260.86511.56428.52
Other Operating Expenses
20.416.4714.4614.2289.1672.75
Operating Expenses
803.67845.03932.06839.81,3501,667
Operating Income
-410.03-484.27-763.4-660.152,2605,820
Interest Expense
-2.42-9.91-19.25-18.12-6.97-0.94
Interest & Investment Income
22.6589.03222.78249.68122.8746.02
Currency Exchange Gain (Loss)
-5.07-5.0744.9187.17495.21-99.72
Other Non Operating Income (Expenses)
-71.28-5.75-0.361.5-2.44-2.09
EBT Excluding Unusual Items
-466.16-415.97-515.32-339.922,8695,763
Impairment of Goodwill
---55.58-57.31-15.41-
Gain (Loss) on Sale of Investments
-2.92-1.610.65-8.991.660.04
Gain (Loss) on Sale of Assets
1.291.750.99-0.64-0.13-0.04
Asset Writedown
-175.04-173.71-26.17-6.09-351.04-
Other Unusual Items
14.336.030.128.72-33.166.71
Pretax Income
-628.49-583.49-585.31-404.232,4715,770
Income Tax Expense
48.6113.91-16.4914.04373.32829.32
Earnings From Continuing Operations
-677.1-597.41-568.82-418.272,0974,941
Minority Interest in Earnings
18.8423.8139.820.69-29.72-20.46
Net Income
-658.27-573.6-529.02-397.582,0684,920
Net Income to Common
-658.27-573.6-529.02-397.582,0684,920
Net Income Growth
-----57.98%193.33%
Shares Outstanding (Basic)
191192197202202202
Shares Outstanding (Diluted)
191192197202202202
Shares Change
-0.69%-2.13%-2.56%0.13%-0.02%2.16%
EPS (Basic)
-3.44-2.98-2.69-1.9710.2624.40
EPS (Diluted)
-3.44-2.98-2.69-1.9710.2624.40
EPS Growth
-----57.97%187.12%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-394.07-501.57-1,272-2,6421,9444,696
Free Cash Flow Per Share
-2.06-2.61-6.47-13.099.6423.29
Dividend Per Share
----1.6673.679
Dividend Growth
-----54.69%47.14%
Gross Margin
39.64%38.08%20.37%21.90%41.18%73.63%
Operating Margin
-41.29%-51.12%-92.21%-80.49%25.78%57.23%
Profit Margin
-66.28%-60.55%-63.90%-48.48%23.58%48.38%
Free Cash Flow Margin
-39.68%-52.94%-153.69%-322.09%22.17%46.18%
EBITDA
-235.53-306.84-582.06-508.832,3385,849
EBITDA Margin
-23.72%-32.39%-70.30%-62.04%26.66%57.52%
D&A For EBITDA
174.5177.43181.34151.3377.8428.77
EBIT
-410.03-484.27-763.4-660.152,2605,820
EBIT Margin
-41.29%-51.12%-92.21%-80.49%25.78%57.23%
Effective Tax Rate
----15.11%14.37%
Revenue as Reported
275.57947.38827.92820.168,76810,169
Advertising Expenses
-24.6922.1424.5213.47-